<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Antifungal susceptibility testing
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Antifungal susceptibility testing
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Antifungal susceptibility testing
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael A Pfaller, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carol A Kauffman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Keri K Hall, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 27, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The need for reproducible, clinically relevant antifungal susceptibility testing has been prompted by the increasing number of invasive fungal infections, the expanding use of new and established antifungal agents, and recognition of antifungal resistance as an important clinical problem [
         <a href="#rid1">
          1-4
         </a>
         ].
        </p>
        <p>
         The collaborative efforts of numerous investigators and the Clinical and Laboratory Standards Institute (CLSI, formerly National Committee for Clinical Laboratory Standards [NCCLS]) Subcommittee on Antifungal Susceptibility Testing have generated consensus documents describing standardized methods for broth- and agar-based antifungal susceptibility testing [
         <a href="#rid5">
          5-9
         </a>
         ]. As a result, in vitro antifungal susceptibility testing plays an increasingly important role in guiding therapeutic decision making, as an aid in drug development studies, and as a means of tracking the development of antifungal resistance in epidemiologic studies [
         <a href="#rid3">
          3,10,11
         </a>
         ].
        </p>
        <p>
         An overview of antifungal susceptibility testing will be presented here. The pharmacology and use of antifungal agents for the treatment of specific fungal infections are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/495.html" rel="external">
          "Pharmacology of azoles"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/476.html" rel="external">
          "Pharmacology of amphotericin B"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/472.html" rel="external">
          "Pharmacology of flucytosine (5-FC)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">
          "Management of candidemia and invasive candidiasis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">
          "Treatment and prevention of invasive aspergillosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2465.html" rel="external">
          "Mucormycosis (zygomycosis)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2426.html" rel="external">
          "Mycology, pathogenesis, and epidemiology of Fusarium infection"
         </a>
         .)
        </p>
        <p>
         An overview of antibacterial susceptibility testing is also presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/467.html" rel="external">
          "Overview of antibacterial susceptibility testing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          OVERVIEW
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Rationale
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary objective of in vitro susceptibility testing is to predict the impact of administration of the tested agent on the outcome of infection caused by the tested organism or similar organisms [
         <a href="#rid3">
          3,12
         </a>
         ]. In this way, antifungal testing is performed for the same reasons that antibacterial testing is performed [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To provide a reliable estimate of the relative activities of two or more antimicrobial agents against the pathogen of interest
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To correlate with in vivo activity and to predict the likely outcome of therapy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To provide a quantitative means by which to survey the development of resistance among a normally susceptible population of organisms
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To predict the therapeutic potential and spectrum of activity of newly developed investigational agents
        </p>
        <p>
        </p>
        <p>
         In the clinical microbiology laboratory, the focus of testing is directed toward a specific clinical isolate causing infection in an individual patient. Studies examining the clinical use of antifungal susceptibility testing have shown that when such testing is available onsite, clinicians find the results helpful and frequently alter therapy based on the results [
         <a href="#rid13">
          13-17
         </a>
         ]. As an example, one study found that susceptibility testing of
         <em>
          Candida glabrata
         </em>
         isolates results in lower overall treatment costs, based on deescalation in therapy from an expensive echinocandin to
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         for patients with documented fluconazole-susceptible
         <em>
          C. glabrata
         </em>
         bloodstream infection [
         <a href="#rid14">
          14
         </a>
         ]. Routine antifungal susceptibility testing can serve as an adjunct in the treatment of candidemia in the same way that antibacterial testing aids in the treatment of bacterial infections [
         <a href="#rid3">
          3,18,19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Limitations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prediction of outcome in a clinical infection from results obtained in an artificial and well-defined matrix (in vitro susceptibility test) is an inherently error-prone process in which only modest degrees of correlation can be expected [
         <a href="#rid3">
          3,12,20,21
         </a>
         ]. Decades of experience with antibacterial susceptibility testing confirm the limited extent of in vitro–in vivo correlation that can be achieved [
         <a href="#rid3">
          3,22-24
         </a>
         ]. Just as in vitro resistance does not always predict clinical failure, so in vitro susceptibility does not ensure successful therapy [
         <a href="#rid3">
          3,25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Clinical relevance
         </span>
         <span class="headingEndMark">
          —
         </span>
         In order to be useful clinically, in vitro susceptibility testing of antimicrobial agents should reliably predict the in vivo response to therapy. However, the in vitro susceptibility of an infecting organism to the antimicrobial agent is only one of several factors that may influence the likelihood that therapy will be successful [
         <a href="#rid3">
          3,11,25-27
         </a>
         ]. Factors related to the host immune response and/or the underlying disease, drug pharmacokinetics and pharmacodynamics, drug interactions, and factors related to the virulence of the infecting organism and its interaction with both the host and the antimicrobial agent administered all influence the outcome of treatment of an infection [
         <a href="#rid3">
          3,11,25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Definitions
         </span>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Minimum inhibitory concentration
         </span>
         <span class="headingEndMark">
          —
         </span>
         The minimum inhibitory concentration (MIC) is the lowest concentration of an antimicrobial agent that inhibits the growth of fungi, as established by a standardized endpoint.
        </p>
        <p>
         The MIC
         <sub>
          50
         </sub>
         is the concentration of an antimicrobial agent at which 50 percent of the organisms tested are inhibited. The MIC
         <sub>
          90
         </sub>
         is the concentration of an antimicrobial agent at which 90 percent of the organisms tested are inhibited.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Minimum effective concentration
         </span>
         <span class="headingEndMark">
          —
         </span>
         The minimum effective concentration (MEC) is defined as the lowest concentration of an echinocandin that results in growth of filamentous fungi producing conspicuously aberrant growth. Aberrant growth of hyphae is defined as small, round, compact microcolonies compared with the matt of hyphal growth in the control well that does not contain an antifungal agent.
        </p>
        <p class="headingAnchor" id="H906841683">
         <span class="h3">
          Clinical breakpoints
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical interpretive MIC breakpoints for in vitro susceptibility testing are used to indicate those isolates that are likely to respond to treatment with a given antimicrobial agent administered using the approved dosing regimen for that agent [
         <a href="#rid25">
          25,28
         </a>
         ]. The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antifungal Susceptibility Testing establishes species-specific clinical breakpoints for the systemically active antifungal agents [
         <a href="#rid6">
          6,9,26,29,30
         </a>
         ]. The clinical breakpoints serve as criteria that not only predict clinical outcome but also improve the sensitivity of the CLSI methods to detect emerging resistance associated with acquired or mutational resistance mechanisms. The clinical breakpoints sort isolates into categories of susceptible (S), susceptible dose dependent (SDD), intermediate (I), and resistant (R).
        </p>
        <p class="headingAnchor" id="H1471001798">
         <span class="h3">
          Epidemiologic cutoff values
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of concern that the clinical breakpoints that have been used in the past may not detect mutational resistance in different species, an extensive effort has been undertaken to establish MICs that are to be expected in wild-type strains that have not been exposed to antifungal agents and that have not acquired resistance mutations. For each species and each antifungal agent, a so-called epidemiologic cutoff value that differentiates the wild-type susceptible strain from those with resistance mutations has been established [
         <a href="#rid4">
          4,25,28,31-33
         </a>
         ]. Epidemiologic cutoff values are the most sensitive measure of the emergence of strains with decreased susceptibility to a given agent [
         <a href="#rid29">
          29,31-37
         </a>
         ] and can be used as a means of tracking the emergence of reduced susceptibility to antifungal agents in surveillance studies [
         <a href="#rid29">
          29,34,35
         </a>
         ]. Epidemiologic cutoff values can also be used to identify isolates that are less likely to respond to therapy when clinical breakpoints cannot be established because of the rarity of infection with unusual species of fungi [
         <a href="#rid25">
          25,26,29-31,34,35
         </a>
         ]. Epidemiologic cutoff values have been established by CLSI for systemically active antifungal agents and several species of
         <em>
          Candida
         </em>
         ,
         <em>
          Cryptococcus
         </em>
         , and
         <em>
          Aspergillus
         </em>
         [
         <a href="#rid38">
          38,39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          INDICATIONS FOR TESTING
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are several situations in which antifungal susceptibility testing should be considered or obtained (
         <a class="graphic graphic_table graphicRef52140" href="/z/d/graphic/52140.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All species of
         <em>
          Candida
         </em>
         isolated from blood or deep sites (eg, normally sterile fluids, tissues, abscesses) should be tested for susceptibility to
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         , and an echinocandin
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mucosal candidiasis that is unresponsive to usual antifungal therapy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Invasive disease that is unresponsive to the initial antifungal regimen
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical failure in patients with invasive disease caused by species with significant rates of acquired resistance (see
         <a class="local">
          'Cross-resistance'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Invasive disease caused by unusual fungal species for which antifungal susceptibility patterns have not been well established or are unpredictable
        </p>
        <p>
        </p>
        <p>
         For species, such as
         <em>
          C. krusei
         </em>
         and
         <em>
          C. auris
         </em>
         that have high rates of intrinsic resistance to
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         , antifungal susceptibility testing should be performed for other azoles, amphotericin B, and the echinocandins, but it is
         <strong>
          not
         </strong>
         necessary to test fluconazole (
         <a class="graphic graphic_table graphicRef52140" href="/z/d/graphic/52140.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          STANDARDIZED METHODS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antifungal susceptibility testing methods for yeasts are comparable with those used for bacteria [
         <a href="#rid3">
          3,19,27
         </a>
         ]. The Clinical and Laboratory Standards Institute (CLSI) has developed and published approved methods for both broth dilution testing [
         <a href="#rid5">
          5,6
         </a>
         ] and disk diffusion testing of yeasts [
         <a href="#rid6">
          6,8
         </a>
         ]. These methods are reproducible, accurate, and available for use in clinical laboratories [
         <a href="#rid11">
          11,26,30,40
         </a>
         ].
        </p>
        <p>
         Standardized methods have also been developed for broth dilution testing [
         <a href="#rid7">
          7
         </a>
         ] and disk diffusion testing of filamentous fungi [
         <a href="#rid9">
          9
         </a>
         ] but require further study to establish the in vivo correlation with in vitro data [
         <a href="#rid41">
          41-44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Broth dilution methods
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the broth macrodilution method, small tubes containing 1 to 2 mL of broth are inoculated with a concentrated antifungal solution and serial twofold dilutions up to eight dilutions. All tubes are then inoculated with a specified amount of the fungal suspension of interest, suspended in an equal volume, and incubated at a given temperature and length of time. The tubes are then examined for turbidity, which represents fungal growth.
        </p>
        <p>
         The broth microdilution method is a modification of the broth macrodilution test and allows for multiple tests to be performed simultaneously in smaller volumes in a 96-well plate.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Yeasts
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both broth macrodilution and microdilution methods for in vitro susceptibility testing of yeasts have been established by the CLSI [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p>
         The microdilution method employs a 24-hour incubation at 35°C and a minimum inhibitory concentration (MIC) endpoint of ≥50 percent inhibition (100 percent inhibition for amphotericin B) relative to the control well that has no antifungal agent added (
         <a class="graphic graphic_picture graphicRef58379" href="/z/d/graphic/58379.html" rel="external">
          picture 1
         </a>
         ). This standardized method provides reliable and reproducible MIC results with good separation of the MIC distribution between wild-type
         <em>
          Candida
         </em>
         isolates that are susceptible and isolates possessing acquired-resistance mutations [
         <a href="#rid45">
          45-49
         </a>
         ]. (See
         <a class="local">
          'Minimum inhibitory concentration'
         </a>
         above.)
        </p>
        <p>
         The MIC clinical breakpoints for systemically active antifungal agents have been developed in accordance with a "blueprint" used for all types of antimicrobial testing [
         <a href="#rid26">
          26,29,30,50,51
         </a>
         ]. This blueprint takes into account data that relate the MICs of the specific agent to known resistance mechanisms, the MIC distribution profiles, consideration of cross-resistance patterns, pharmacokinetic (PK) and pharmacodynamic (PD) parameters, and the relationship between in vitro activity (ie, MIC) and clinical outcome according to individual species, as determined by the available clinical efficacy studies [
         <a href="#rid11">
          11,26,30
         </a>
         ]. MIC breakpoints have been developed for six antifungal agents for the following
         <em>
          Candida
         </em>
         spp:
         <em>
          C. albicans
         </em>
         ,
         <em>
          C. glabrata
         </em>
         ,
         <em>
          C. parapsilosis
         </em>
         ,
         <em>
          C. tropicalis
         </em>
         ,
         <em>
          C. krusei
         </em>
         , and
         <em>
          C. guilliermondii
         </em>
         (
         <a class="graphic graphic_table graphicRef82995" href="/z/d/graphic/82995.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         In 2010 and 2011, the CLSI Subcommittee on Antifungal Susceptibility Testing established new
         <em>
          Candida
         </em>
         species-specific clinical breakpoints for
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         [
         <a href="#rid29">
          29
         </a>
         ],
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         [
         <a href="#rid30">
          30
         </a>
         ], and the echinocandins [
         <a href="#rid26">
          26
         </a>
         ]. This change was made due to the recognition that MICs for the various agents were significantly lower for some species than others and that the previous clinical breakpoints for susceptibility of &lt;8 mcg/mL for fluconazole, &lt;1 mcg/mL for voriconazole and &lt;2 mcg/mL for the echinocandins were not appropriate for all species.
        </p>
        <p>
         The updated clinical breakpoints are shown in the table (
         <a class="graphic graphic_table graphicRef82995" href="/z/d/graphic/82995.html" rel="external">
          table 2
         </a>
         ); the general patterns are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         , the clinical breakpoints for susceptible (S), susceptible dose dependent (SDD), and resistant (R), respectively, are the same values for
         <em>
          C. albicans
         </em>
         ,
         <em>
          C. tropicalis
         </em>
         , and
         <em>
          C. parapsilosis
         </em>
         and much higher for
         <em>
          C. glabrata
         </em>
         , reflecting the need to use higher doses (12 mg/kg per day) of fluconazole if this agent is used in the management of C. glabrata infection [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         , the clinical breakpoints are the same values for
         <em>
          C. albicans
         </em>
         ,
         <em>
          C. parapsilosis
         </em>
         , and
         <em>
          C. tropicalis
         </em>
         and are slightly higher for
         <em>
          C. krusei
         </em>
         . Given the low clinical response of cases of invasive candidiasis due to
         <em>
          C. glabrata
         </em>
         to voriconazole and the lack of any correlation between clinical response and MIC, the CLSI Subcommittee for Antifungal Testing has not set a clinical breakpoint for
         <em>
          C. glabrata
         </em>
         [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         , the clinical breakpoints are similar for
         <em>
          C. albicans
         </em>
         ,
         <em>
          C. tropicalis
         </em>
         , and
         <em>
          C. krusei
         </em>
         and are higher for
         <em>
          C. parapsilosis
         </em>
         and
         <em>
          C. guilliermondii
         </em>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For
         <em>
          C. glabrata
         </em>
         , the clinical breakpoints vary for each echinocandin.
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          Caspofungin
         </a>
         susceptibility testing in vitro has been associated with significant interlaboratory variability, contributing to reports of false resistance when using the reference method described in CLSI document M27 [
         <a href="#rid52">
          52
         </a>
         ]. When testing caspofungin, susceptible results may be reported as "susceptible"; however, laboratories should confirm "intermediate" or "resistant" results by performing additional susceptibility testing with
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         [
         <a href="#rid53">
          53
         </a>
         ] or
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         [
         <a href="#rid54">
          54
         </a>
         ], DNA sequence analysis of
         <em>
          FKS
         </em>
         genes to identify resistance hot spot mutations in
         <em>
          FKS1
         </em>
         (all
         <em>
          Candida
         </em>
         species) and
         <em>
          FKS2
         </em>
         (
         <em>
          C. glabrata
         </em>
         only) [
         <a href="#rid55">
          55,56
         </a>
         ], or sending the isolate to a reference laboratory for confirmation.
         <em>
          Candida
         </em>
         species resistant to anidulafungin or micafungin or possessing characteristic
         <em>
          FKS
         </em>
         hot spot mutations are considered resistant to all echinocandins, including caspofungin, and should be reported as such [
         <a href="#rid53">
          53,54
         </a>
         ].
        </p>
        <p>
         These clinical breakpoints are only applicable to the species listed above due to the lack of outcomes data for the less common species.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Filamentous fungi
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antifungal susceptibility testing may be useful in guiding the selection of antifungal agents for the treatment of invasive disease [
         <a href="#rid57">
          57-59
         </a>
         ]. This is especially true for
         <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">
          isavuconazole
         </a>
         [
         <a href="#rid60">
          60
         </a>
         ],
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         , and the echinocandins, all of which have varying degrees of activity against opportunistic molds [
         <a href="#rid43">
          43,57-59,61-63
         </a>
         ].
        </p>
        <p>
         Using the broth microdilution method for yeasts as a template [
         <a href="#rid5">
          5
         </a>
         ], the CLSI Subcommittee on Antifungal Susceptibility Testing developed a standardized method for filamentous fungi [
         <a href="#rid7">
          7
         </a>
         ]. This method is applicable for testing most rapidly growing molds, including
         <em>
          Aspergillus
         </em>
         spp,
         <em>
          Fusarium
         </em>
         spp,
         <em>
          Paecilomyces
         </em>
         spp,
         <em>
          Scedosporium
         </em>
         spp,
         <em>
          Trichoderma
         </em>
         spp, several dematiaceous (brown-black) molds, and the Mucorales [
         <a href="#rid7">
          7,31,42,43
         </a>
         ].
        </p>
        <p>
         The MIC endpoint criterion for molds is the lowest drug concentration that shows complete growth inhibition when testing amphotericin B,
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">
          isavuconazole
         </a>
         [
         <a href="#rid60">
          60
         </a>
         ],
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         [
         <a href="#rid7">
          7,43
         </a>
         ]. Several multicenter studies have documented the reproducibility of this method [
         <a href="#rid41">
          41-43,64
         </a>
         ] and have shown promise in predicting antifungal efficacy [
         <a href="#rid65">
          65,66
         </a>
         ].
        </p>
        <p>
         One area of concern has been the difficulty in standardizing this method for determining the in vitro susceptibility of
         <em>
          Aspergillus
         </em>
         spp to the echinocandins [
         <a href="#rid45">
          45,67
         </a>
         ]. It is generally agreed that the proper antifungal endpoint for the echinocandins when testing
         <em>
          Aspergillus
         </em>
         spp and other molds is the minimum effective concentration (MEC) [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="local">
          'Minimum effective concentration'
         </a>
         above.)
        </p>
        <p>
         In a comparative study, the use of the MEC endpoint criteria resulted in excellent agreement among 14 of 17 participating laboratories when a panel of 20 isolates of
         <em>
          Aspergillus
         </em>
         spp was tested against
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         [
         <a href="#rid45">
          45
         </a>
         ]. Thus, for echinocandin testing with
         <em>
          Aspergillus
         </em>
         spp, the MEC offers an endpoint that can give generally reproducible results. However, the finding of aberrant results in 3 of the 17 laboratories suggests a need for caution and further refinement of the echinocandin test method for
         <em>
          Aspergillus
         </em>
         spp and other filamentous fungi [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         Interpretive breakpoints based on the correlation of in vitro data with clinical outcome have been established for
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         and
         <em>
          Aspergillus fumigatus
         </em>
         (Susceptible ≤0.5 mg/L; Intermediate 1 mg/L; Resistant ≥2 mg/L) but have not been established for other mold-drug combinations [
         <a href="#rid27">
          27,68-71
         </a>
         ]. Clinical failure with amphotericin B has been associated with MICs of &gt;1 mcg/mL for
         <em>
          Aspergillus fumigatus
         </em>
         ,
         <em>
          A. terreus
         </em>
         ,
         <em>
          Fusarium
         </em>
         spp, and
         <em>
          Lomentospora
         </em>
         (formerly
         <em>
          Scedoporium
         </em>
         )
         <em>
          prolificans
         </em>
         [
         <a href="#rid64">
          64,66,68
         </a>
         ]. Clinical failures of
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         in the treatment of aspergillosis have been associated with MICs of &gt;8 mcg/mL [
         <a href="#rid63">
          63,68
         </a>
         ]. Studies of resistance mechanisms in
         <em>
          A. fumigatus
         </em>
         have shown that MIC cut-offs of ≤1 mcg/mL for
         <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">
          isavuconazole
         </a>
         , itraconazole, and voriconazole and ≤0.25 mcg/mL for
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         provided separation of the susceptible population from strains with resistance mutations of the CYP51A gene [
         <a href="#rid63">
          63
         </a>
         ]. This is clinically relevant because certain mutations of the CYP51A gene result in predictable patterns of cross-resistance among the azoles. (See
         <a class="local">
          'Cross-resistance'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Disk diffusion methods
         </span>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Yeasts
         </span>
         <span class="headingEndMark">
          —
         </span>
         Agar disk diffusion testing has been used for many years as a simple, flexible, and cost-effective alternative to broth dilution testing of antibacterial agents [
         <a href="#rid72">
          72,73
         </a>
         ]. This method has also been incorporated into the CLSI-approved guidelines for antifungal susceptibility testing of yeasts [
         <a href="#rid6">
          6,8
         </a>
         ]. Zone diameter reference ranges have been defined for
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         when tested against
         <em>
          Candida
         </em>
         spp [
         <a href="#rid26">
          26,29,30,74-77
         </a>
         ].
        </p>
        <p>
         Following 24 hours of incubation at 35ºC, the zone diameters surrounding disks are measured to the nearest millimeter at the point at which there is a prominent reduction in growth (
         <a class="graphic graphic_picture graphicRef50544" href="/z/d/graphic/50544.html" rel="external">
          picture 2
         </a>
         ).
        </p>
        <p>
         The 24-hour zone diameters correlate well with both 24- and 48-hour reference MICs and have allowed the establishment of interpretive breakpoints for
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         [
         <a href="#rid11">
          11,26,28,30,77
         </a>
         ].
        </p>
        <p>
         Although not standardized for testing of yeasts other than
         <em>
          Candida
         </em>
         , the same disk test method has also been shown to be a useful approach for determining the susceptibility of
         <em>
          Cryptococcus neoformans
         </em>
         and other non-candidal yeasts to
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         and
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         [
         <a href="#rid78">
          78-80
         </a>
         ]. The interpretation of such results remains under investigation [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Filamentous fungi
         </span>
         <span class="headingEndMark">
          —
         </span>
         The CLSI Subcommittee on Antifungal Susceptibility Testing has proposed guidelines for disk diffusion testing of filamentous fungi against
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         , amphotericin B, and
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         , based upon the results of a multicenter collaborative study [
         <a href="#rid9">
          9,81
         </a>
         ]. The clinical relevance of testing the filamentous fungi remains uncertain because interpretive breakpoints with proven clinical value have yet to be identified or approved by the CLSI or any other regulatory agency [
         <a href="#rid9">
          9,81
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          COMMERCIAL MIC METHODS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Three commercial products have been approved by the United States Food and Drug Administration (FDA) for testing the susceptibility of clinical isolates of
         <em>
          Candida
         </em>
         to
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         and
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         : the Etest (bioMerieux), the Sensititre YeastOne colorimetric plate (TREK Diagnostic Systems) and the VITEK 2 yeast susceptibility test (bioMerieux). The Sensititre YeastOne system and the Etest are also FDA-approved for testing susceptibility to
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         and
         <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">
          flucytosine
         </a>
         . The Sensititre and Vitek 2 systems are also approved for testing
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         .
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Etest
         </span>
         <span class="headingEndMark">
          —
         </span>
         Etest is the most sensitive and reliable method for detecting decreased susceptibility to amphotericin B among isolates of
         <em>
          Candida
         </em>
         spp and
         <em>
          Cryptococcus neoformans
         </em>
         [
         <a href="#rid82">
          82-84
         </a>
         ]. Etest can be used for testing filamentous fungi, such as
         <em>
          Aspergillus
         </em>
         spp and the Mucorales [
         <a href="#rid44">
          44,64
         </a>
         ]; however, it is not FDA approved for this purpose.
        </p>
        <p>
         The Etest method is based upon the establishment of a stable concentration gradient of an antimicrobial agent following diffusion from a plastic strip into an agar medium. When an Etest strip is placed upon an agar plate that has been inoculated with a test organism and incubated for 24 to 48 hours, an ellipse of growth inhibition occurs, and the intersection of the ellipse with the numeric scale on the strip provides an indication of the minimum inhibitory concentration (MIC) (
         <a class="graphic graphic_picture graphicRef66713" href="/z/d/graphic/66713.html" rel="external">
          picture 3
         </a>
         ).
        </p>
        <p>
         The Etest method is applicable to antifungal susceptibility testing of both yeasts and molds. Numerous studies demonstrate the usefulness of Etest for determining the in vitro activity of a variety of antifungal agents including amphotericin B,
         <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">
          flucytosine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         [
         <a href="#rid44">
          44,64,82,84-89
         </a>
         ]. MICs determined by Etest generally agree well with those determined by the broth dilution reference method; however, this agreement may vary depending upon the antifungal agent tested, the choice of agar medium, and the fungal species [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Sensititre YeastOne panel
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Sensititre YeastOne panel is available in a dry-form, 96-well tray with a colorimetric growth indicator. It has excellent accuracy and reproducibility and has been used widely in the United States and elsewhere for testing of
         <em>
          Candida
         </em>
         and
         <em>
          Cryptococcus neoformans
         </em>
         [
         <a href="#rid40">
          40,91
         </a>
         ]. Following the addition of a broth inoculum suspension and 24-hour incubation, colorimetric MIC results are read at the first well showing a color change of red (growth) to purple (growth inhibition) or blue (no growth).
        </p>
        <p>
         In addition to
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">
          flucytosine
         </a>
         , the YeastOne panel may include amphotericin B,
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         . In a series of multicenter studies, excellent agreement was observed between broth microdilution and YeastOne MIC results for the triazoles (95 percent agreement) and the three echinocandins (100 percent agreement) [
         <a href="#rid92">
          92,93
         </a>
         ].
        </p>
        <p>
         In addition to providing highly reproducible MIC results that reliably predict the MICs determined by the reference broth microdilution method, the YeastOne system provides results for all classes of antifungal agents (polyenes,
         <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">
          flucytosine
         </a>
         , triazoles, and echinocandins) within 24 hours.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          VITEK 2 yeast susceptibility test
         </span>
         <span class="headingEndMark">
          —
         </span>
         The spectrophotometric approach to antifungal susceptibility testing has been shown to be valid and feasible for use in the clinical laboratory [
         <a href="#rid94">
          94,95
         </a>
         ] and is an integral component of the European Committee on Antibiotic Susceptibility Testing (EUCAST) method [
         <a href="#rid94">
          94-96
         </a>
         ].
        </p>
        <p>
         The VITEK 2 yeast susceptibility system, which determines growth spectrophotometrically, is the first commercially available automated approach to antifungal susceptibility testing and provides optimal test standardization. It performs fully automated antifungal susceptibility testing of
         <em>
          Candida
         </em>
         spp against five antifungal agents (
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         , and
         <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">
          flucytosine
         </a>
         ) [
         <a href="#rid97">
          97-100
         </a>
         ]. The VITEK 2 system has been updated to reflect revised CLSI clinical breakpoints for fluconazole [
         <a href="#rid101">
          101
         </a>
         ]. This system allows clinical laboratories to perform yeast identification and susceptibility testing simultaneously [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
         Notably, the VITEK 2 system has not been shown to be capable of reliable detection of resistance to the echinocandins [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
         Multicenter evaluations have shown agreement of greater than 95 percent in comparisons of the VITEK 2 yeast susceptibility system MICs with reference broth microdilution MICs for the seven antifungal agents used [
         <a href="#rid97">
          97,98,100
         </a>
         ]. The VITEK 2 system is rapid, with a mean time to results of 12 to 15 hours [
         <a href="#rid97">
          97,98,100
         </a>
         ]. The availability of rapid quantitative antifungal susceptibility results will be a major step in optimizing the treatment of invasive candidal infections.
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          FUNGICIDAL ACTIVITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         In certain clinical situations, the ability of the antimicrobial agent to kill the pathogen may be important [
         <a href="#rid103">
          103,104
         </a>
         ]. These situations involve infection of a site not easily accessed by host defenses and/or of a structure with essential anatomic or physiologic function, such as the heart, central nervous system, or bone. In addition, infections in immunocompromised hosts, especially those who are neutropenic, are often thought to require microbicidal therapy [
         <a href="#rid103">
          103,104
         </a>
         ]. Furthermore, a microbicidal regimen may prevent the development of resistance [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p>
         These issues have given rise to a perceived need to assess the fungicidal activity of both new and established antifungal agents against opportunistic pathogens [
         <a href="#rid104">
          104,106
         </a>
         ].
        </p>
        <p>
         By rigorously following a common procedure, various laboratories may reliably perform and interpret both time-kill and minimum fungicidal concentration determinations with
         <em>
          Candida
         </em>
         and
         <em>
          Aspergillus
         </em>
         spp [
         <a href="#rid104">
          104
         </a>
         ]. In standardizing in vitro fungicidal tests, considerable effort must be undertaken to ensure that agents classified as fungicidal by in vitro methods do in fact clear involved organs of the infecting organism in animal models of infection. Even if all of these requirements are met, there is no assurance that such in vitro testing will be meaningful clinically.
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          SUSCEPTIBILITY PATTERNS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many fungal species have predictable antifungal susceptibility patterns. However, rising rates of resistance to antifungal agents have occurred among some fungal species due to the increase in the immunocompromised population and the frequent use of
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         and the echinocandins.
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Candida spp
         </span>
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h3">
          Amphotericin B
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among the various species of
         <em>
          Candida
         </em>
         ,
         <em>
          C. albicans
         </em>
         remains the most susceptible to amphotericin B. The minimum inhibitory concentration (MIC) that encompasses 90 percent of isolates tested (MIC
         <sub>
          90
         </sub>
         ) is 0.5 mcg/mL (
         <a class="graphic graphic_table graphicRef51523" href="/z/d/graphic/51523.html" rel="external">
          table 3
         </a>
         ). Although interpretive breakpoints for amphotericin B have not been established, isolates of
         <em>
          Candida
         </em>
         for which MICs are &gt;2 mcg/mL are unusual and possibly resistant or, at the very least, may require high doses of amphotericin B for optimal treatment [
         <a href="#rid37">
          37
         </a>
         ]. Both
         <em>
          C. glabrata
         </em>
         and
         <em>
          C. krusei
         </em>
         exhibit decreased susceptibility to amphotericin B compared with
         <em>
          C. albicans
         </em>
         (
         <a class="graphic graphic_table graphicRef51523" href="/z/d/graphic/51523.html" rel="external">
          table 3
         </a>
         ).
         <em>
          C. lusitaniae
         </em>
         generally appears susceptible to amphotericin B upon initial isolation from blood, but resistance frequently develops during treatment (
         <a class="graphic graphic_table graphicRef51523" href="/z/d/graphic/51523.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid107">
          107
         </a>
         ]. The emerging pathogen,
         <em>
          C. auris
         </em>
         ,
         <em>
         </em>
         exhibits amphotericin B resistance rates of approximately 30 percent in the United States, based on an MIC breakpoint of ≥2 mcg/mL [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h3">
          Azoles
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          Fluconazole
         </a>
         MICs are usually ≤2 mcg/mL for
         <em>
          C. albicans
         </em>
         ,
         <em>
          C. parapsilosis
         </em>
         ,
         <em>
          C. tropicalis
         </em>
         , and
         <em>
          C. lusitaniae
         </em>
         . Reduced susceptibility to fluconazole is common among isolates of
         <em>
          C. glabrata
         </em>
         and
         <em>
          C. guilliermondii
         </em>
         (
         <a class="graphic graphic_table graphicRef51523" href="/z/d/graphic/51523.html" rel="external">
          table 3
         </a>
         ).
         <em>
          C. auris
         </em>
         exhibits markedly reduced susceptibility to fluconazole with US resistance rates of 90 percent, defined as an MIC ≥32 mcg/ML [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
         <em>
          C. krusei
         </em>
         is considered to be intrinsically resistant to
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         ;
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         have significantly greater potency than fluconazole against
         <em>
          Candida
         </em>
         spp, including some species, such as
         <em>
          C. krusei
         </em>
         and
         <em>
          C. guilliermondii
         </em>
         , that have reduced susceptibility to fluconazole [
         <a href="#rid107">
          107,109,110
         </a>
         ]. MIC
         <sub>
          90
         </sub>
         values are generally &lt;1 mcg/mL for these agents for most species of
         <em>
          Candida
         </em>
         , with the exception of
         <em>
          C. glabrata
         </em>
         and
         <em>
          C. auris
         </em>
         (
         <a class="graphic graphic_table graphicRef51523" href="/z/d/graphic/51523.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid108">
          108,111
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h3">
          Echinocandins
         </span>
         <span class="headingEndMark">
          —
         </span>
         All three echinocandins exhibit excellent potency against
         <em>
          Candida
         </em>
         spp (
         <a class="graphic graphic_table graphicRef51523" href="/z/d/graphic/51523.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid112">
          112
         </a>
         ].
         <em>
          C. albicans
         </em>
         ,
         <em>
          C. glabrata
         </em>
         , and
         <em>
          C. tropicalis
         </em>
         are highly susceptible to all three agents, whereas elevated MICs are seen for
         <em>
          C. parapsilosis
         </em>
         and
         <em>
          C. guilliermondii
         </em>
         . Acquired resistance to the echinocandins remains sporadic [
         <a href="#rid4">
          4,113
         </a>
         ] but has been documented for individual cases of infection with
         <em>
          C. albicans
         </em>
         ,
         <em>
          C. auris
         </em>
         ,
         <em>
          C. glabrata
         </em>
         ,
         <em>
          C. lusitaniae
         </em>
         ,
         <em>
          C. tropicalis
         </em>
         , and
         <em>
          C. parapsilosis
         </em>
         [
         <a href="#rid114">
          114-121
         </a>
         ]. There is increasing concern that some
         <em>
          C. glabrata
         </em>
         bloodstream isolates with resistance to
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         and
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         are also resistant to the echinocandins [
         <a href="#rid121">
          121,122
         </a>
         ]. This is a serious concern and argues for continued surveillance for resistance using standardized antifungal susceptibility testing. (See
         <a class="local">
          'Echinocandins'
         </a>
         below.)
        </p>
        <p>
         Species-specific echinocandin clinical breakpoints were developed to improve the sensitivity of the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method to identify strains of
         <em>
          Candida
         </em>
         with acquired resistance mutations in the
         <em>
          FKS
         </em>
         gene [
         <a href="#rid26">
          26,28
         </a>
         ]. Conversely, strains for which echinocandin MICs fall into the susceptible category are considered wild-type strains that do not possess acquired resistance mutations. Mutations in
         <em>
          FKS
         </em>
         in isolates of
         <em>
          C. albicans
         </em>
         ,
         <em>
          C. glabrata
         </em>
         ,
         <em>
          C. tropicalis
         </em>
         ,
         <em>
          C. krusei
         </em>
         ,
         <em>
          C. lusitaniae
         </em>
         ,
         <em>
          C. dubliniensis
         </em>
         , and
         <em>
          C. kefyr
         </em>
         have been associated with elevated echinocandin MICs and a poor clinical response [
         <a href="#rid26">
          26,49,114-120
         </a>
         ].
        </p>
        <p>
         In an international surveillance study that evaluated the frequency of echinocandin resistance using the clinical breakpoints, resistance remained quite low (0.0 to 0.7 percent) for isolates from 2006 to 2016 of all of these species, with the exception of
         <em>
          C. glabrata
         </em>
         [
         <a href="#rid123">
          123
         </a>
         ]. Echinocandin resistance among
         <em>
          C. glabrata
         </em>
         isolates varied according to geographic origin from 0 percent in Latin America to 2.8 percent in North America [
         <a href="#rid124">
          124
         </a>
         ]. Strains with echinocandin MICs in the resistant category were documented to contain mutations in either
         <em>
          FKS1
         </em>
         or
         <em>
          FKS2
         </em>
         .
        </p>
        <p>
         A 10-year study of
         <em>
          C. glabrata
         </em>
         bloodstream infections at a single medical center in the United States showed an increase in echinocandin resistance from 4.9 percent in 2001 to 12.3 percent in 2010 [
         <a href="#rid121">
          121
         </a>
         ]. This resistance was confirmed by the presence of
         <em>
          FKS
         </em>
         mutations; strains categorized as susceptible did not possess acquired mutations. On multivariate analysis, echinocandin resistance was associated with prior exposure to an echinocandin. Among 118 episodes of
         <em>
          C. glabrata
         </em>
         infection in which the infecting strain was categorized as susceptible using the clinical breakpoints, 109 (92.4 percent) had successful outcomes at day 10 of treatment with
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         . Conversely, among 13 episodes of
         <em>
          C. glabrata
         </em>
         infection in which the strain was categorized as resistant using the clinical breakpoints and treated with micafungin monotherapy, 5 (38.5 percent) did not respond or responded initially but relapsed or recurred. The CLSI clinical breakpoints differentiate wild-type strains from strains bearing clinically significant
         <em>
          FKS
         </em>
         mutations.
        </p>
        <p>
         Additional studies of echinocandin resistance among
         <em>
          C. glabrata
         </em>
         isolates are presented separately.
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h3">
          Flucytosine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">
          Flucytosine
         </a>
         is generally quite active against most species of
         <em>
          Candida
         </em>
         with 95 percent of clinical isolates tested being susceptible with an MIC of ≤4 mcg/mL [
         <a href="#rid125">
          125
         </a>
         ]. Flucytosine MICs are generally very low for
         <em>
          C. albicans
         </em>
         ,
         <em>
          C. glabrata
         </em>
         ,
         <em>
          C. parapsilosis
         </em>
         ,
         <em>
          C. tropicalis
         </em>
         ,
         <em>
          C. guilliermondii
         </em>
         , and
         <em>
          C. lusitaniae
         </em>
         (
         <a class="graphic graphic_table graphicRef51523" href="/z/d/graphic/51523.html" rel="external">
          table 3
         </a>
         ). In contrast, resistance to flucytosine is common among isolates of
         <em>
          C. krusei
         </em>
         .
        </p>
        <p>
         The choice of antifungal regimen for infections caused by each of the
         <em>
          Candida
         </em>
         species described above is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">
          "Management of candidemia and invasive candidiasis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h2">
          Other yeasts
         </span>
         <span class="headingEndMark">
          —
         </span>
         In contrast with
         <em>
          Candida
         </em>
         spp, the non-candidal yeasts comprise a very diverse collection of opportunistic pathogens [
         <a href="#rid80">
          80,110
         </a>
         ]. It is important to understand that
         <em>
          Cryptococcus
         </em>
         ,
         <em>
          Trichosporon
         </em>
         ,
         <em>
          Rhodotorula
         </em>
         , and
         <em>
          Saprochaetae
         </em>
         (formerly
         <em>
          Blastoschizomyces
         </em>
         ) spp are intrinsically resistant to the echinocandin class of agents [
         <a href="#rid126">
          126
         </a>
         ]. Amphotericin B is generally active against these organisms with the notable exception of
         <em>
          Trichosporon asahii
         </em>
         , which should be considered resistant to amphotericin B (
         <a class="graphic graphic_table graphicRef71985" href="/z/d/graphic/71985.html" rel="external">
          table 4
         </a>
         ). MICs for
         <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">
          flucytosine
         </a>
         are generally &lt;1 mcg/mL for isolates of
         <em>
          Rhodotorula
         </em>
         and
         <em>
          Saccharomyces
         </em>
         spp but are &gt;4 mcg/mL for
         <em>
          C. neoformans
         </em>
         and
         <em>
          S. capitata
         </em>
         .
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          Fluconazole
         </a>
         MICs are moderately elevated (MIC
         <sub>
          90
         </sub>
         <em>
          S. capitata
         </em>
         [formerly
         <em>
          Blastoschizomyces
         </em>
         ]
         <em>
         </em>
         = 8 mcg/mL) for isolates of
         <em>
          C. neoformans
         </em>
         ,
         <em>
          Trichosporon
         </em>
         spp,
         <em>
          Saccharomyces
         </em>
         spp, and
         <em>
          S. capitata
         </em>
         (
         <a class="graphic graphic_table graphicRef71985" href="/z/d/graphic/71985.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid127">
          127-136
         </a>
         ]. Aside from
         <em>
          Rhodotorula
         </em>
         spp, which are resistant to all azoles,
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         are very active against the non-candidal yeasts (
         <a class="graphic graphic_table graphicRef71985" href="/z/d/graphic/71985.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h2">
          Molds
         </span>
         <span class="headingEndMark">
          —
         </span>
         Amphotericin B is generally active against
         <em>
          Aspergillus
         </em>
         spp (
         <a class="graphic graphic_table graphicRef82439" href="/z/d/graphic/82439.html" rel="external">
          table 5
         </a>
         ); however, certain non-fumigatus
         <em>
          Aspergillus
         </em>
         species, such as
         <em>
          A. terreus,
         </em>
         are considered to be resistant to amphotericin B [
         <a href="#rid137">
          137
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">
          "Treatment and prevention of invasive aspergillosis", section on 'Consideration of antifungal resistance'
         </a>
         .)
        </p>
        <p>
         MICs for amphotericin B are low for the Mucorales, whereas
         <em>
          Fusarium
         </em>
         spp,
         <em>
          S. apiospermum,
         </em>
         and
         <em>
          Lomentospora
         </em>
         (formerly
         <em>
          Scedoporium
         </em>
         )
         <em>
          prolificans
         </em>
         are considered resistant to this agent (
         <a class="graphic graphic_table graphicRef82439" href="/z/d/graphic/82439.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p>
         All of the triazoles have potent activity against
         <em>
          Aspergillus
         </em>
         spp. [
         <a href="#rid61">
          61,138
         </a>
         ].
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          Voriconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">
          isavuconazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         generally are more active than
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         against
         <em>
          Fusarium
         </em>
         and
         <em>
          L. prolificans
         </em>
         [
         <a href="#rid60">
          60,61,138,139
         </a>
         ]. Posaconazole, isavuconazole, and voriconazole are active against
         <em>
          S. apiospermum
         </em>
         , whereas only posaconazole and isavuconazole show activity against the Mucorales.
        </p>
        <p>
         The MEC for
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         and the other echinocandins is usually quite low for
         <em>
          Aspergillus
         </em>
         spp but is elevated for the non-
         <em>
          Aspergillus
         </em>
         molds (
         <a class="graphic graphic_table graphicRef82439" href="/z/d/graphic/82439.html" rel="external">
          table 5
         </a>
         ). The echinocandins are not recommended as first-line therapy for infections caused by
         <em>
          Aspergillus
         </em>
         spp since their efficacy for this indication has not been established. (See
         <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">
          "Treatment and prevention of invasive aspergillosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h1">
          CROSS-RESISTANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because the azole class of antifungal agents shares a common mechanism of action and (in most cases) of resistance, there is concern regarding the development of cross-resistance among the azoles with both
         <em>
          Candida
         </em>
         and
         <em>
          Aspergillus
         </em>
         spp [
         <a href="#rid10">
          10,63,140,141
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H33">
         <span class="h2">
          Candida spp
         </span>
        </p>
        <p class="headingAnchor" id="H34">
         <span class="h3">
          Azoles
         </span>
         <span class="headingEndMark">
          —
         </span>
         The potential for cross-resistance among the available triazoles is evident, especially among
         <em>
          Candida
         </em>
         spp capable of overexpression of
         <em>
          Candida
         </em>
         drug resistance (CDR) efflux pumps (eg,
         <em>
          C. glabrata
         </em>
         ) and, to a lesser extent, those with overexpression of and/or mutation in the target enzyme, lanosterol 14-alpha-demethylase [
         <a href="#rid140">
          140,142,143
         </a>
         ].
        </p>
        <p>
         Among
         <em>
          Candida
         </em>
         isolates, there is a strong positive correlation between
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         minimum inhibitory concentrations (MICs) and those of
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         , indicating considerable cross-resistance [
         <a href="#rid140">
          140,144
         </a>
         ]. Thus, resistance to fluconazole may serve as a surrogate marker in predicting resistance to the other extended-spectrum triazoles with
         <em>
          Candida
         </em>
         spp. An analysis of cross-resistance among fluconazole and the other triazoles demonstrated that isolates of
         <em>
          Candida
         </em>
         spp for which fluconazole MICs are ≥64 mcg/mL (resistant) also tend to be less susceptible to itraconazole [
         <a href="#rid140">
          140,145
         </a>
         ], voriconazole [
         <a href="#rid79">
          79,140
         </a>
         ], and posaconazole [
         <a href="#rid140">
          140,144
         </a>
         ]. Fluconazole MICs of ≤32 mcg/mL predict susceptibility, and MICs of ≥64 mcg/mL predict resistance of
         <em>
          Candida
         </em>
         spp to voriconazole and posaconazole [
         <a href="#rid140">
          140,144
         </a>
         ].
        </p>
        <p>
         Certain
         <em>
          Candida
         </em>
         species have predictable patterns of cross-resistance. Notably, none of the triazoles exhibit meaningful activity against fluconazole-resistant isolates of
         <em>
          C. glabrata
         </em>
         , whereas
         <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">
          isavuconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         are active against the intrinsically fluconazole-resistant
         <em>
          C. krusei
         </em>
         [
         <a href="#rid140">
          140,146
         </a>
         ].
        </p>
        <p>
         Evidence supporting the clinical relevance of azole cross-resistance has been documented in case reports and case series of invasive candidiasis in which clinically significant microbial resistance to
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         has been reported among critically ill patients and immunocompromised patients with a history of substantial recent azole exposure, such as
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         , before voriconazole is given [
         <a href="#rid140">
          140,141
         </a>
         ]. These concerns have led some experts to suggest fluconazole susceptibility testing of initial blood isolates of
         <em>
          Candida
         </em>
         as a means of identifying those patients who may not respond optimally to either voriconazole or
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         therapy [
         <a href="#rid14">
          14,16,141
         </a>
         ].
        </p>
        <p>
         There is increasing concern that some
         <em>
          C. glabrata
         </em>
         bloodstream isolates with resistance to
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         and
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         are also resistant to the echinocandins [
         <a href="#rid122">
          122
         </a>
         ]. (See
         <a class="local">
          'Echinocandins'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H35">
         <span class="h3">
          Echinocandins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cross-resistance among echinocandins has been documented and is usually related to mutations in the
         <em>
          FKS1
         </em>
         (glucan synthase) gene [
         <a href="#rid46">
          46,47,147
         </a>
         ]. A 16- to 128-fold change in MIC relative to the MIC of a fully susceptible wild-type strain is consistently observed for all three echinocandins when tested against a
         <em>
          Candida
         </em>
         strain with
         <em>
          FKS1
         </em>
         mutations [
         <a href="#rid147">
          147
         </a>
         ]. The MICs for
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         and
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         tend to be somewhat higher than those determined for
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         in such strains [
         <a href="#rid147">
          147
         </a>
         ].
        </p>
        <p>
         The clinical significance of such differences remains to be determined; however, the more conservative approach would be to consider those isolates shown to be resistant to either
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         or
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         to be resistant to the other agents in the class.
        </p>
        <p>
         There is increasing concern that some
         <em>
          C. glabrata
         </em>
         bloodstream isolates with resistance to
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         and
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         are also resistant to the echinocandins. Such resistance is termed co-resistance (rather than cross-resistance) because the resistance to the echinocandins involves a different mechanism than the resistance to the azoles. In a surveillance study of the in vitro susceptibility of 1669
         <em>
          C. glabrata
         </em>
         bloodstream isolates collected in the United States between 2006 and 2010, 162 isolates (9.7 percent) were resistant to fluconazole, of which 98.8 percent were also not susceptible to voriconazole (MIC &gt;0.5 mcg/mL), and 9.3, 9.3, and 8.0 percent were resistant to
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         , respectively [
         <a href="#rid122">
          122
         </a>
         ]. Of the 162 isolates that were resistant to fluconazole, 18 (11.1 percent) were resistant to one or more of the echinocandins; all of these isolates contained an
         <em>
          FKS1
         </em>
         or
         <em>
          FKS2
         </em>
         mutation. In comparison, there were no echinocandin-resistant strains detected among 110 fluconazole-resistant
         <em>
          C. glabrata
         </em>
         isolates tested between 2001 and 2004, years during which only one echinocandin, caspofungin, was available and echinocandins were used sparingly. At this point, it is not clear what impact these findings will have on treatment regimens for candidemia.
        </p>
        <p>
         In a study of
         <em>
          C. glabrata
         </em>
         bloodstream infections at a single medical center in the United States conducted between 2001 and 2010, among 78 fluconazole-resistant isolates, 11 (14.1 percent) were resistant to one or more echinocandins and 8 (10.3 percent) were resistant to all echinocandins [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H36">
         <span class="h2">
          Filamentous fungi
         </span>
         <span class="headingEndMark">
          —
         </span>
         Investigation of azole cross-resistance among filamentous fungi has focused on studies of
         <em>
          Aspergillus fumigatus
         </em>
         [
         <a href="#rid63">
          63,140,148
         </a>
         ]. Cross-resistance among the triazoles is dependent upon specific mutations in the
         <em>
          A. fumigatus
         </em>
         <em>
          CYP51A
         </em>
         gene [
         <a href="#rid63">
          63
         </a>
         ]. Certain mutations result in cross-resistance between
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         but not
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         [
         <a href="#rid63">
          63
         </a>
         ]. Other mutations may result in resistance to itraconazole and voriconazole but not posaconazole. Still other mutations result in resistance to all four triazoles [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         Given the lack of complete cross-resistance among the azoles for
         <em>
          Aspergillus
         </em>
         spp, antifungal susceptibility testing is warranted to identify resistant phenotypes in patients with invasive disease who have clinical failure of initial therapy [
         <a href="#rid63">
          63
         </a>
         ]. (See
         <a class="local">
          'Indications for testing'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H37">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Importance of susceptibility testing
         </strong>
         – The need for reproducible, clinically relevant antifungal susceptibility testing has been prompted by the increasing number of invasive fungal infections, the expanding use of new and established antifungal agents, and recognition of antifungal resistance as an important clinical problem. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Development of susceptibility standards
         </strong>
         – The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antifungal Susceptibility Testing has generated consensus documents describing standardized methods for broth- and agar-based antifungal susceptibility testing. As a result, in vitro antifungal susceptibility testing plays an increasingly important role in guiding therapeutic decision making, as an aid in drug development studies, and as a means of tracking the development of antifungal resistance in epidemiologic studies. Several commercial methods for antifungal susceptibility testing are available. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Standardized methods'
         </a>
         above and
         <a class="local">
          'Commercial MIC methods'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical relevance
         </strong>
         – In order to be useful clinically, in vitro susceptibility testing of antimicrobial agents should reliably predict the in vivo response to therapy. The in vitro susceptibility of an infecting organism to the antimicrobial agent is only one of several factors that may influence the likelihood that therapy will be successful. (See
         <a class="local">
          'Clinical relevance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for susceptibility testing
         </strong>
         – There are several situations in which antifungal susceptibility testing should be considered or obtained (
         <a class="graphic graphic_table graphicRef52140" href="/z/d/graphic/52140.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         All species of
         <em>
          Candida
         </em>
         isolated from blood or deep sites (eg, normally sterile fluids, tissues, abscesses) should be tested for susceptibility to
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         , and an echinocandin. For species, such as
         <em>
          C. krusei
         </em>
         and
         <em>
          C. auris
         </em>
         that have high rates of intrinsic resistance to fluconazole, antifungal susceptibility testing should be performed for other azoles, amphotericin B, and the echinocandins, but it is
         <strong>
          not
         </strong>
         necessary to test fluconazole (
         <a class="graphic graphic_table graphicRef52140" href="/z/d/graphic/52140.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mucosal candidiasis that is unresponsive to usual antifungal therapy
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Invasive disease that is unresponsive to the initial antifungal regimen
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Clinical failure in patients with invasive disease caused by species with significant rates of acquired resistance (see
         <a class="local">
          'Cross-resistance'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Invasive disease caused by unusual fungal species for which antifungal susceptibility patterns have not been well established or are unpredictable
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Susceptibility patterns
         </strong>
         – Many fungal species have predictable antifungal susceptibility patterns. However, rising rates of resistance to antifungal agents have occurred among some fungal species due to the increase in the immunocompromised population and the frequent use of
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         and echinocandins. (See
         <a class="local">
          'Susceptibility patterns'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cross-resistance
         </strong>
         – Cross-resistance is a concern, particularly among the azole antifungal agents. (See
         <a class="local">
          'Cross-resistance'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Johnson EM. Issues in antifungal susceptibility testing. J Antimicrob Chemother 2008; 61 Suppl 1:i13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA. New developments in the antifungal susceptibility testing of Candida. Curr Fungal Infect Reports 2008; 2:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002; 35:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012; 125:S3.
          </a>
         </li>
         <li class="breakAll">
          Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard, 4th ed, CLSI document M27, Clinical and Laboratory Standards Institute, Wayne, PA 2017.
         </li>
         <li class="breakAll">
          Clinical and Laboratory Standards Institute. Performance standards for antifungal susceptibility testing of yeasts, 2nd ed. CLSI supplement M60 Clinical and Laboratory Standards Institute, Wayne, PA 2020.
         </li>
         <li class="breakAll">
          Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; Approved standard, 3rd ed, CLSI document M38, Clinical and Laboratory Standards Institute, Wayne, PA 2017.
         </li>
         <li class="breakAll">
          Clinical and Laboratory Standards Institute. Method for antifungal disk diffusion susceptibility testing of yeasts, 3rd ed. CLSI document M44, Clinical and Laboratory Standards Institute, Wayne, PA 2020.
         </li>
         <li class="breakAll">
          Clinical and Laboratory Standards Institute. Performance standards for antifungal susceptibility testing of filamentous fungi, 2nd ed. CLSI supplement M61 Clinical and Laboratory Standards Institute, Wayne, PA 2020.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanafani ZA, Perfect JR. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 2008; 46:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baddley JW, Patel M, Jones M, et al. Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia. Diagn Microbiol Infect Dis 2004; 50:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collins CD, Eschenauer GA, Salo SL, Newton DW. To test or not to test: a cost minimization analysis of susceptibility testing for patients with documented Candida glabrata fungemias. J Clin Microbiol 2007; 45:1884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadley S, Martinez JA, McDermott L, et al. Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients. J Antimicrob Chemother 2002; 49:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007; 60:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magill SS, Shields C, Sears CL, et al. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006; 44:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armstrong-James D. Invasive Candida species infection: the importance of adequate empirical antifungal therapy. J Antimicrob Chemother 2007; 60:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forrest G. Role of antifungal susceptibility testing in patient management. Curr Opin Infect Dis 2006; 19:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA. Antifungal susceptibility testing methods. Curr Drug Targets 2005; 6:929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Rex JH, Rinaldi MG. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis 1997; 24:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arikan S. Current status of antifungal susceptibility testing methods. Med Mycol 2007; 45:569.
          </a>
         </li>
         <li class="breakAll">
          Sanders WE Jr, Sanders CC. Do in vitro antimicrobial susceptibility tests accurately predict therapeutic responsiveness in infected patients?. In: Significance of medical microbiology in the care of patients, 2nd ed, Lorian V (Ed), Williams &amp; Wilkins, Baltimore 1982. p.325.
         </li>
         <li class="breakAll">
          Diekama DJ, Pfaller MA. Utility of antifungal suceptibility testing and clinical correlations. In: Interactions of yeasts, moulds, and antifungal agents: How to detect resistance, Hall GS (Ed), Springer, 2012.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 2007; 20:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011; 14:164.
          </a>
         </li>
         <li class="breakAll">
          Johnson EM, Arendrup MC. Susceptibility test methods: Yeasts and filamentous fungi. In: Manual of Clinical Microbiology, 12th ed, Jorgensen JH, Pfaller MA (Eds), ASM Press, Washington, DC 2019. p.2351.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 2012; 50:2846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Andes D, Diekema DJ, et al. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010; 13:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Andes D, Arendrup MC, et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 2011; 70:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahlmeter G, Brown DF, Goldstein FW, et al. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 2003; 52:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simjee S, Silley P, Werling HO, Bywater R. Potential confusion regarding the term 'resistance' in epidemiological surveys. J Antimicrob Chemother 2008; 61:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turnidge J, Kahlmeter G, Kronvall G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 2006; 12:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Boyken L, Hollis RJ, et al. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol 2010; 48:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Boyken L, Hollis RJ, et al. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution. J Clin Microbiol 2011; 49:630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Castanheira M, Diekema DJ, et al. Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida. J Clin Microbiol 2011; 49:3800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Espinel-Ingroff A, Canton E, et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol 2012; 50:2040.
          </a>
         </li>
         <li class="breakAll">
          Clinical and Laboratory Standards Institute. Principles and procedures for the development of epidemiological cutoff values for antifungal susceptibility testing, 1st ed. CLSI Guideline M57 Clinical and Laboratory Standards Institute, Wayne, PA 2016.
         </li>
         <li class="breakAll">
          Clinical and Laboratory Standards Institute. Epidemiological cutoff values for antifungal susceptibility testing, 4th ed. CLSI supplement M57S Clinical and Laboratory Standards Institute, Wayne, PA, 2022.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Jones RN, Microbiology Resource Committee, College of American Pathologists. Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists Microbiology Surveys Program (2001-2003). Arch Pathol Lab Med 2006; 130:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinel-Ingroff A, Dawson K, Pfaller M, et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995; 39:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinel-Ingroff A, Bartlett M, Bowden R, et al. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol 1997; 35:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinel-Ingroff A, Bartlett M, Chaturvedi V, et al. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards. Antimicrob Agents Chemother 2001; 45:1828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinel-Ingroff A. Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B. J Clin Microbiol 2006; 44:3616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Odds FC, Motyl M, Andrade R, et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol 2004; 42:3475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006; 50:2058.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005; 49:3264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Castanheira M, Diekema DJ, et al. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J Clin Microbiol 2010; 48:1592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perlin D. Echinocandin-resistant Candida: molecular methods and phenotypes. Curr Fungal Infect Reports 2011; 5:113.
          </a>
         </li>
         <li class="breakAll">
          Clinical and Laboratory Standards Institute. Development of in vitro susceptibility testing criteria and quality control parameters; Approved guideline, 4th edition, CLSI document M23. Clinical and Laboratory Standards Institute, Wayne, PA 2016.
         </li>
         <li class="breakAll">
          Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 30th ed. CLSI supplement M100 Clinical and Laboratory Standards Institute, Wayne, PA 2020.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinel-Ingroff A, Arendrup MC, Pfaller MA, et al. Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother 2013; 57:5836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Messer SA, Diekema DJ, et al. Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria. J Clin Microbiol 2014; 52:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Diekema DJ, Jones RN, Castanheira M. Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria. J Clin Microbiol 2014; 52:3223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arendrup MC, Perlin DS. Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis 2014; 27:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Effron G, Lee S, Park S, et al. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother 2009; 53:3690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alastruey-Izquierdo A, Cuenca-Estrella M, Monzón A, et al. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother 2008; 61:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, et al. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother 2008; 52:1244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castelli MV, Alastruey-Izquierdo A, Cuesta I, et al. Susceptibility testing and molecular classification of Paecilomyces spp. Antimicrob Agents Chemother 2008; 52:2926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Messer SA, Rhomberg PR, et al. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J Clin Microbiol 2013; 51:2608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41:3623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Messer SA, Boyken L, et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 2008; 46:2568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, et al. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2008; 52:2468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinel-Ingroff A. Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J Clin Microbiol 2003; 41:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Odds FC, Van Gerven F, Espinel-Ingroff A, et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother 1998; 42:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lass-Flörl C, Kofler G, Kropshofer G, et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 1998; 42:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartizal C, Odds FC. Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob Agents Chemother 2003; 47:2100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mosquera J, Denning DW. Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2002; 46:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinel-Ingroff A, Diekema DJ, Fothergill A, et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol 2010; 48:3251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinel-Ingroff A, Fothergill A, Fuller J, et al. Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother 2011; 55:2855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinel-Ingroff A, Cuenca-Estrella M, Fothergill A, et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother 2011; 55:5150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones RN, College of American Pathologists Microbiology Resource Committe. Method preferences and test accuracy of antimicrobial susceptibility testing: updates from the College of Amercian Pathologists Microbiology Surveys Program. Arch Pathol Lab Med 2001; 125:1285.
          </a>
         </li>
         <li class="breakAll">
          Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests: Approved standard, 13th ed. CLSI document M02. Clinical and Laboratory Standards Institute, Wayne, PA 2018.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barry A, Bille J, Brown S, et al. Quality control limits for fluconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue. J Clin Microbiol 2003; 41:3410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Barry A, Bille J, et al. Quality control limits for voriconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue. J Clin Microbiol 2004; 42:1716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown S, Traczewski M. Quality control limits for posaconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue. J Clin Microbiol 2007; 45:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown SD, Traczewski MM. Caspofungin disk diffusion breakpoints and quality control. J Clin Microbiol 2008; 46:1927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Diekema DJ, Rinaldi MG, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005; 43:5848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007; 45:1735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2009; 47:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinel-Ingroff A, Arthington-Skaggs B, Iqbal N, et al. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin. J Clin Microbiol 2007; 45:1811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wanger A, Mills K, Nelson PW, Rex JH. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother 1995; 39:2520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baker CN, Stocker SA, Culver DH, Thornsberry C. Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol 1991; 29:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lozano-Chiu M, Paetznick VL, Ghannoum MA, Rex JH. Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin Microbiol 1998; 36:2817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clancy CJ, Nguyen MH. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia. Antimicrob Agents Chemother 1999; 43:1289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Boyken L, Messer SA, et al. Evaluation of the etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species. J Clin Microbiol 2004; 42:4977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander BD, Byrne TC, Smith KL, et al. Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J Clin Microbiol 2007; 45:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chryssanthou E, Cuenca-Estrella M. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol 2002; 40:3841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinel-Ingroff A, Rezusta A. E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method. J Clin Microbiol 2002; 40:2101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinel-Ingroff A, Pfaller M, Erwin ME, Jones RN. Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose. J Clin Microbiol 1996; 34:848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morace G, Amato G, Bistoni F, et al. Multicenter comparative evaluation of six commercial systems and the national committee for clinical laboratory standards m27-a broth microdilution method for fluconazole susceptibility testing of Candida species. J Clin Microbiol 2002; 40:2953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Espinel-Ingroff A, Jones RN. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole. J Clin Microbiol 2004; 42:4577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Chaturvedi V, Diekema DJ, et al. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. J Clin Microbiol 2008; 46:2155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuenca-Estrella M, Lee-Yang W, Ciblak MA, et al. Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species. Antimicrob Agents Chemother 2002; 46:3644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, et al. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 2005; 43:3884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuenca-Estrella M, Moore CB, Barchiesi F, et al. Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect 2003; 9:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J Clin Microbiol 2007; 45:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J Clin Microbiol 2007; 45:3522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aubertine CL, Rivera M, Rohan SM, Larone DH. Comparative study of the new colorimetric VITEK 2 yeast identification card versus the older fluorometric card and of CHROMagar Candida as a source medium with the new card. J Clin Microbiol 2006; 44:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peterson JF, Pfaller MA, Diekema DJ, et al. Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp. J Clin Microbiol 2011; 49:1765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Diekema DJ, Procop GW, Wiederhold NP. Multicenter evaluation of the new Vitek 2 yeast susceptibility test using new CLSI clinical breakpoints for fluconazole. J Clin Microbiol 2014; 52:2126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Astvad KM, Perlin DS, Johansen HK, et al. Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common candida species. Antimicrob Agents Chemother 2013; 57:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peterson LR, Shanholtzer CJ. Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance. Clin Microbiol Rev 1992; 5:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Sheehan DJ, Rex JH. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev 2004; 17:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stratton CW. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis 2003; 9:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20:133.
          </a>
         </li>
         <li class="breakAll">
          Candida auris: Antifungal susceptibility testing and interpretation. Centers for Disease Control and Prevention (CDC). https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html (Accessed on February 16, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Diekema DJ, International Fungal Surveillance Participant Group. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004; 10 Suppl 1:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42:4419.
          </a>
         </li>
         <li class="breakAll">
          Candida auris: Treatment and management of infections and colonization. Centers for Disease Control and Prevention (CDC). https://www.cdc.gov/fungal/candida-auris/c-auris-treatment.html (Accessed on February 16, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun HY, Singh N. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int J Antimicrob Agents 2010; 35:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapeland-Leclerc F, Hennequin C, Papon N, et al. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob Agents Chemother 2010; 54:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, et al. Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg Infect Dis 2012; 18:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dodgson KJ, Dodgson AR, Pujol C, et al. Caspofungin resistant C. glabrata. Clin Microbiol Infect 2005; 11 (Suppl 2):364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kofteridis DP, Lewis RE, Kontoyiannis DP. Caspofungin-non-susceptible Candida isolates in cancer patients. J Antimicrob Chemother 2010; 65:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006; 42:938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Castanheira M, Lockhart SR, et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50:1199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimbeck AJ, Iqbal N, Ahlquist AM, et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother 2010; 54:5042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013; 56:1724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Castanheira M, Lockhart SR, et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50:1199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Messer SA, Woosley LN, et al. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 2013; 51:2571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Diekema DJ, Turnidge JD, et al. Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997-2016. Open Forum Infect Dis 2019; 6:S79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 2002; 46:3518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007; 45:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Messer SA, Boyken L, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005; 43:2163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arikan S, Hasçelik G. Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates. Diagn Microbiol Infect Dis 2002; 43:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 2002; 46:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serena C, Pastor FJ, Ortoneda M, et al. In vitro antifungal susceptibilities of uncommon basidiomycetous yeasts. Antimicrob Agents Chemother 2004; 48:2724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asada N, Uryu H, Koseki M, et al. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin Infect Dis 2006; 43:e39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diekema DJ, Petroelje B, Messer SA, et al. Activities of available and investigational antifungal agents against rhodotorula species. J Clin Microbiol 2005; 43:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zerva L, Hollis RJ, Pfaller MA. In vitro susceptibility testing and DNA typing of Saccharomyces cerevisiae clinical isolates. J Clin Microbiol 1996; 34:3031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Messer S, Jones RN. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother 1997; 41:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swinne D, Watelle M, Nolard N. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates. Rev Iberoam Micol 2005; 22:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Diekema DJ, Merz WG. Infections due to emerging non-Candida, non-Cryptococcus opportunistic yeast pathogens. Curr Fungal Infect Reports 2007; 1:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50:2009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008; 21:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Diekema DJ. Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance. J Invasive Fungal Infect 2007; 1:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander BD, Schell WA, Miller JL, et al. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 2005; 80:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lupetti A, Danesi R, Campa M, et al. Molecular basis of resistance to azole antifungals. Trends Mol Med 2002; 8:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Messer SA, Boyken L, et al. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol 2008; 46:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. J Clin Microbiol 2005; 43:3807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Rhomberg PR, Wiederhold NP, et al. In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories. Antimicrob Agents Chemother 2018; 62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mellado E, Garcia-Effron G, Alcázar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007; 51:1897.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 465 Version 34.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18063599" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Issues in antifungal susceptibility testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : New developments in the antifungal susceptibility testing of Candida
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12355386" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Has antifungal susceptibility testing come of age?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22196207" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22196207" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22196207" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22196207" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22196207" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22196207" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18171227" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16614256" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11585779" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Antifungal susceptibility testing: practical aspects and current challenges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15474321" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17409208" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : To test or not to test: a cost minimization analysis of susceptibility testing for patients with documented Candida glabrata fungemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11815592" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17576697" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16455909" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17646200" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Invasive Candida species infection: the importance of adequate empirical antifungal therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17075328" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Role of antifungal susceptibility testing in patient management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16375676" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Antifungal susceptibility testing methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9142769" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Antifungal susceptibility testing: technical advances and potential clinical applications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17885947" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Current status of antifungal susceptibility testing methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17885947" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Current status of antifungal susceptibility testing methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17885947" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Current status of antifungal susceptibility testing methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17630331" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Setting and revising antibacterial susceptibility breakpoints.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21353623" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21353623" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22740712" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21050800" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21546199" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12837738" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18029414" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Potential confusion regarding the term 'resistance' in epidemiological surveys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16643517" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19923478" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21159940" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21900519" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22461672" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22461672" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22461672" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16740026" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists Microbiology Surveys Program (2001-2003).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7726488" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8968895" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11353633" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16943356" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15297486" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16723566" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16048935" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20335424" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Echinocandin-resistant Candida: molecular methods and phenotypes
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Echinocandin-resistant Candida: molecular methods and phenotypes
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Echinocandin-resistant Candida: molecular methods and phenotypes
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24018263" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24153129" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24951808" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25304391" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Echinocandin resistance: an emerging clinical problem?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19546367" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18263569" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18212093" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18519716" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Susceptibility testing and molecular classification of Paecilomyces spp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23740727" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12904365" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18562581" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18474574" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12517880" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9527773" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9818749" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12821453" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11796377" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Azole cross-resistance in Aspergillus fumigatus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20592159" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21422219" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21876047" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11570902" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Method preferences and test accuracy of antimicrobial susceptibility testing: updates from the College of Amercian Pathologists Microbiology Surveys Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11570902" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Method preferences and test accuracy of antimicrobial susceptibility testing: updates from the College of Amercian Pathologists Microbiology Surveys Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12843106" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Quality control limits for fluconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15071030" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Quality control limits for voriconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17093031" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Quality control limits for posaconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18400918" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Caspofungin disk diffusion breakpoints and quality control.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16333066" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17442797" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19005141" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17428932" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8585737" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2037671" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9738026" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10223955" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15528683" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Evaluation of the etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17202279" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12354895" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12037072" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8815095" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12149358" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Multicenter comparative evaluation of six commercial systems and the national committee for clinical laboratory standards m27-a broth microdilution method for fluconazole susceptibility testing of Candida species.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15472311" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18463213" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12384382" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16081926" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12848721" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17215344" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17913927" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16390976" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Comparative study of the new colorimetric VITEK 2 yeast identification card versus the older fluorometric card and of CHROMagar Candida as a source medium with the new card.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21430096" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24719450" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Multicenter evaluation of the new Vitek 2 yeast susceptibility test using new CLSI clinical breakpoints for fluconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23089746" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common candida species.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1423219" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15084501" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12533275" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11230410" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17223626" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Epidemiology of invasive candidiasis: a persistent public health problem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17223626" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Epidemiology of invasive candidiasis: a persistent public health problem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14748799" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15472288" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15472288" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18032613" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20036518" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20038613" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22257484" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Candida spp. with acquired echinocandin resistance, France, 2004-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Caspofungin resistant C. glabrata
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20016020" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Caspofungin-non-susceptible Candida isolates in cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16511756" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22278842" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20837754" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23487382" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22278842" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23720791" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30895218" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12384359" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17510856" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Nosocomial fungal infections: epidemiology, diagnosis, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15872236" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12088616" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11897610" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : In vitro antifungal susceptibilities of Trichosporon species.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15215135" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : In vitro antifungal susceptibilities of uncommon basidiomycetous yeasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16838224" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15635020" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Activities of available and investigational antifungal agents against rhodotorula species.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8940443" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : In vitro susceptibility testing and DNA typing of Saccharomyces cerevisiae clinical isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9021172" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15813679" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Infections due to emerging non-Candida, non-Cryptococcus opportunistic yeast pathogens
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27365388" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16723559" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18202441" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Infections caused by Scedosporium spp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16210978" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11815273" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Molecular basis of resistance to azole antifungals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9564569" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18094129" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16081915" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30061288" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17569573" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Resistance to echinocandin-class antifungal drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17371828" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
